Efficacy and Safety of Pioglitazone Therapy for Chronic Granulomatous Disease Patients With Severe Infection
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Pioglitazone (Primary)
- Indications Chronic granulomatous disease
- Focus Therapeutic Use
- 19 Oct 2019 Status changed from recruiting to discontinued.
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.
- 07 May 2017 Planned End Date changed from 31 Dec 2019 to 31 Aug 2020.